Status:
COMPLETED
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborating Sponsors:
Institut de Cancérologie de la Loire
Groupe de Recherche sur la Thrombose
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Patients with Multiple Myeloma (MM) are at increased risk of venous thromboembolic event, especially in newly diagnosed patients and during induction treatment with thalidomide in combination with dex...
Eligibility Criteria
Inclusion
- Inscription to medical assurance
- Patients who gave their written consent
- Patients with newly diagnosed Multiple Myeloma required chemotherapy
Exclusion
- Patients with renal failure who need to undergo hemodialysis
- Patients with indication for curative anticoagulant therapy
- Patient with 3 month follow-up not possible
- Patient with life expectancy \< 6 month
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT01508416
Start Date
January 1 2012
End Date
June 1 2015
Last Update
July 28 2015
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Clermont Ferrand
Clermont-Ferrand, France, 63000
2
CHU de Nancy
Nancy, France, 54000
3
Service de Médecine Interne - CHU de Saint Etienne
Saint-Etienne, France, 42055
4
Service de rhumatologie - CHU de Saint Etienne
Saint-Etienne, France, 42055